Fiagon Exit
Fiagon develops a new medical navigation system for intraoperative process control and positioning of instruments for ENT, head-/ neck- and neurosurgery.
Press releases
Press
Successful Exit for High-Tech Gründerfonds – Intersect ENT acquires Fiagon
Buyer is the Intersect ENT, a medical technology company based in the USThe startup Fiagon AG Medical Technologies expands Intersects portfolio of ENT product offeringsFor the HTGF it is the 8th successful exit during the Corona crisis
The High-Tech Gründerfonds sold its shares in Fiagon. The seed investor has accompanied the company for 11 years. The publicly traded company Intersect ENT (NASDAQ: XENT), Menlo Park, California, USA, is dedicated to transforming the treatment of ear
Press
The HTGF-portfolio company FIAGON AG SECURES A PATENT LICENSE AGREEMENT WITH GE HEALTHCARE, AND FIAGON AG HAS RECEIVED NOTICE OF 510(k) CLEARANCE FROM THE FDA as well as chinese CFDA approval
GE Healthcare and Fiagon AG Announce a Patent License Agreement
Fiagon AG today announced that it has entered into an agreement with GE Healthcare. Under the terms of the agreement, Fiagon will acquire a patent license to several of GE Healthcare’s ENT and Cranial navigation technologies. This will help Fiagon surround and back up the 35 issued patents and substantial intellectual property of Fiagon, resulting in greater protection from competitive interference by other companies.
This ag
Info & Contact
Address
Neuendorfstraße 23b
16761 Henningsdorf
16761 Henningsdorf
In portfolio
15. Jun 2009 – 12. Sep 2020
Sector
HTGF Manager
Exit